Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for KYTX is 18.72M and currently, short sellers hold a 15.76% of that float. On January 24, 2025, KYTX’s average trading volume was 322.70K shares.
KYTX) stock’s latest price update
The stock price of Kyverna Therapeutics Inc (NASDAQ: KYTX) has surged by 3.24 when compared to previous closing price of 3.39, but the company has seen a 2.04% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-24 that NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=124941&wire=1 or contact Joseph E. Levi, Esq.
KYTX’s Market Performance
Kyverna Therapeutics Inc (KYTX) has seen a 2.04% rise in stock performance for the week, with a -12.50% decline in the past month and a -32.69% plunge in the past quarter. The volatility ratio for the week is 7.82%, and the volatility levels for the past 30 days are at 7.65% for KYTX. The simple moving average for the last 20 days is -3.37% for KYTX stock, with a simple moving average of -58.35% for the last 200 days.
Analysts’ Opinion of KYTX
Many brokerage firms have already submitted their reports for KYTX stocks, with UBS repeating the rating for KYTX by listing it as a “Buy.” The predicted price for KYTX in the upcoming period, according to UBS is $13 based on the research report published on October 10, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see KYTX reach a price target of $16. The rating they have provided for KYTX stocks is “Buy” according to the report published on October 09th, 2024.
H.C. Wainwright gave a rating of “Neutral” to KYTX, setting the target price at $8 in the report published on July 03rd of the previous year.
KYTX Trading at -17.76% from the 50-Day Moving Average
After a stumble in the market that brought KYTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.02% of loss for the given period.
Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 7.82%, as shares sank -10.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.84% lower at present.
During the last 5 trading sessions, KYTX rose by +2.04%, which changed the moving average for the period of 200-days by -84.97% in comparison to the 20-day moving average, which settled at $3.62. In addition, Kyverna Therapeutics Inc saw -6.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYTX starting from Vida Ventures, LLC, who purchase 253,136 shares at the price of $22.00 back on Feb 12 ’24. After this action, Vida Ventures, LLC now owns 252,553 shares of Kyverna Therapeutics Inc, valued at $5,568,992 using the latest closing price.
Bain Capital Life Sciences Inv, the 10% Owner of Kyverna Therapeutics Inc, purchase 450,000 shares at $22.00 during a trade that took place back on Feb 12 ’24, which means that Bain Capital Life Sciences Inv is holding 3,163,868 shares at $9,900,000 based on the most recent closing price.
Stock Fundamentals for KYTX
The total capital return value is set at -0.4.
Based on Kyverna Therapeutics Inc (KYTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -10.48. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -758.89.
Currently, EBITDA for the company is -58.47 million with net debt to EBITDA at 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.50.
Conclusion
To wrap up, the performance of Kyverna Therapeutics Inc (KYTX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
